LFCR
NASDAQ · Life Sciences Tools & Services
Lifecore Biomedical Inc
$7.57
+0.01 (+0.13%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 330.32M | 344.67M | 265.26M |
| Net Income | 13.34M | 18.11M | 14.22M |
| EPS | — | — | — |
| Profit Margin | 4.0% | 5.3% | 5.4% |
| Rev Growth | +9.8% | +6.7% | +0.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 35.92M | 31.30M | 33.69M |
| Total Equity | 171.45M | 172.81M | 150.13M |
| D/E Ratio | 0.21 | 0.18 | 0.22 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 27.35M | 26.32M | 22.29M |
| Free Cash Flow | 12.88M | 8.29M | 10.33M |